1. Protein Tyrosine Kinase/RTK
  2. Ephrin Receptor

ALW-II-41-27 (Synonyms: Eph receptor tyrosine kinase inhibitor)

Cat. No.: HY-18007 Purity: 99.38%
Handling Instructions

ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor, used for cancer treatment.

For research use only. We do not sell to patients.
ALW-II-41-27 Chemical Structure

ALW-II-41-27 Chemical Structure

CAS No. : 1186206-79-0

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 495 In-stock
5 mg USD 370 In-stock
10 mg USD 475 In-stock
50 mg USD 1280 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

    ALW-II-41-27 purchased from MCE. Usage Cited in: Oncogene. 2017 Oct 5;36(40):5620-5630.

    C3-TAg cells are starved and stimulated for 0, 15 and 30 min with ephrin-A1-Fc (EphA2 ligand; 1 μg/mL) in the presence or absence of ALW-II-41-27 or NG-25 control. EphA2 is immunoprecipitated and products probed for tyrosine phosphorylation and EphA2. ALW-II-41-27 significantly reduces basal and ephrin-A1-Fc induced tyrosine phosphorylation.

    ALW-II-41-27 purchased from MCE. Usage Cited in: Nat Commun. 2017 Jun 6;8:15729.

    EphA2 immunoprecipitates prepared from MCF-7 cells expressing ectopic EphA2 are immunoblotted with anti-phosphotyrosine and anti-EphA2 antibody. The indicated samples are treated with recombinant human ephrin-A1 (500 ng/mL) for 20 min. Eight-hour pre-treatment with the EphA2 inhibitor ALW-II-41-27 (100 nM) suppressed ephrin-A1-induced EphA2 phosphorylation.

    ALW-II-41-27 purchased from MCE. Usage Cited in: Oncotarget. 2017 Nov 1;8(61):104330-104346.

    MC38-CT or -CC1-L cells are treated with 1 μM of DMSO, or the non-specific NG-25 or specific ALW-II-41-27 EPHA2 receptor inhibitor for indicated periods of time, followed by stimulation with EFNA1-Fc (2 μg/mL) in the last 15 min of treatments. Protein lysates are prepared and subjected to immunoblotting using antibodies to determine the effect of kinase inhibitors on EPHA2 activation.

    Featured Recommendations

    Related Small Molecules:

    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor, used for cancer treatment.

    In Vitro

    ALW-II-41-27 inhibits Ba/F3 cells transformed with Tel fusions of EphA3, Kit, Fms, KDR, FLT1, FGR, Src, Lyn, Bmx, and Bcr-Abl with an EC50 below 500 nM. ALW-II-41-27 exhibits cross reactivity with Bcr-Abl. ALW-II-41-27 inhibits b-raf, CSF1R, DDR1, DDR2, EphA2, EphA5, EphA8, EphB1, EphB2, EphB3, Frk, Kit, Lck, p38α, p38β, PDGFRα, PDGFRβ, and Raf1 and many more demonstrating how introduction of the thiophene group can have a tremendous impact on kinase selectivity[1].

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 1.6456 mL 8.2279 mL 16.4558 mL
    5 mM 0.3291 mL 1.6456 mL 3.2912 mL
    10 mM 0.1646 mL 0.8228 mL 1.6456 mL
    Please refer to the solubility information to select the appropriate solvent.
    Molecular Weight




    CAS No.




    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 47 mg/mL

    ALW-II-41-27 is prepared in 10% 1-methyl-2-pyrrolidinone and 90% polyethylene glycol 300[2].

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.


    Purity: 99.38%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.: